Stocks and Investing Stocks and Investing
Tue, May 9, 2023

Andrew Fein Reiterated (ACAD) at Strong Buy and Held Target at $28 on, May 9th, 2023


Published on 2024-10-28 03:32:45 - WOPRAI, Andrew Fein
  Print publication without navigation


Andrew Fein of HC Wainwright & Co., Reiterated "ACADIA Pharmaceuticals Inc." (ACAD) at Strong Buy and Held Target at $28 on, May 9th, 2023.

Andrew has made no other calls on ACAD in the last 4 months.



There are 8 other peers that have a rating on ACAD. Out of the 8 peers that are also analyzing ACAD, 6 agree with Andrew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Uy Ear of "Mizuho" Reiterated at Hold and Held Target at $20 on, Friday, April 14th, 2023
  • Julio Romero of "JP Morgan" Maintained at Hold with Increased Target to $21 on, Monday, March 20th, 2023
  • Tazeen Ahmad of "B of A Securities" Maintained at Hold and Held Target at $23 on, Tuesday, March 14th, 2023
  • Jeffrey Hung of "Morgan Stanley" Maintained at Hold with Increased Target to $20 on, Tuesday, March 14th, 2023
  • Jay Olson of "Oppenheimer" Maintained at Hold with Increased Target to $20 on, Wednesday, March 1st, 2023
  • Jason West of "JMP Securities" Maintained at Hold with Decreased Target to $22 on, Tuesday, February 28th, 2023


These are the ratings of the 2 analyists that currently disagree with Andrew


  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $26 on, Tuesday, March 14th, 2023
  • Charles Duncan of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $33 on, Tuesday, March 14th, 2023
Contributing Sources